|
WO2021061554A1
|
|
Ibudilast oral formulations and methods of using same
|
|
US2020121659A1
|
|
Methods of treating ophthalmic disease/disorder or injury with ibudilast
|
|
US2020108123A1
|
|
Combination of ibudilast and interferon-beta and methods of using same
|
|
WO2019157428A1
|
|
Methods of suppressing myeloid-derived suppressor cells in patients
|
|
WO2019157423A1
|
|
Methods and dosing regimens using ibudilast and a second agent for cancer therapy
|
|
EP3558301A1
|
|
Methods of treating glioblastoma multiforme using ibudilast
|
|
EP3454853A1
|
|
Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
|
|
BR112017010700A2
|
|
combination of ibudilaste and riluzole and methods of use thereof
|
|
WO2016085994A1
|
|
Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
|
|
WO2016085981A1
|
|
Method of inhibiting or treating fibrosis
|
|
WO2016085954A1
|
|
Geranygeranylacetone and analogs thereof and phenoxyalkylcarboxlic acids for treating fibrosis
|
|
WO2016086000A1
|
|
A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
|
|
WO2015195822A1
|
|
A combination of geranylgeranylacetone and ibudilast and methods of using same
|
|
EP3148523A1
|
|
Method of inhibiting or treating fibrosis
|
|
WO2015171765A2
|
|
Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
|
|
US2015322004A1
|
|
Method of treating advanced non-alcoholic steatohepatitis
|
|
US2015321989A1
|
|
Method of treating idiopathic pulmonary fibrosis
|
|
US2015051191A1
|
|
Treatment of alcoholism using ibudilast
|
|
CA2917780A1
|
|
Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
|
|
US2014155484A1
|
|
Method of treating liver disorders
|
